Among a small cohort of healthy Korean male volunteers, evogliptin combined with empagliflozin or dapagliflozin had no significant effects on the pharmacokinetics (PK) of each drug. In healthy male ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...

Researchers conducted a target trial emulation using Danish healthcare data to compare the effectiveness of empagliflozin and dapagliflozin in improving kidney outcomes among patients with T2D. They ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Although low-dose dapagliflozin was less effective in preventing hospitalization for heart failure, SGLT-2 inhibitors had similar cardiovascular outcomes in T2D. Canagliflozin and dapagliflozin ...

As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...